Briefly, using the CRC organoid platform, MCLA-158 was identified as a therapeutic EGFR × Lgr5 bispecific antibody from 500 effective bAbs against epithelial tumors by Herpers B et al. (Herpers et al., 2022). Here, LGR5 is linked to colorectal carcinoma.